Patient selection: myelodysplastic syndrome
Measure of fatigue: EORTC QLQ-C30 (quality of life questionnaire, core 30, European Organisation for Research and Treatment of Cancer)
In Figure 2, increasing fatigue was associated with increased mortality in 6 months, 1 year and 2 years.
percent mortality within 2 years =
= (0.48 * (fatigue score)) + 43
Additional factors associated with worse overall survival:
(1) high risk by IPSS (on multivariate analysis)
(2) transfusion dependence (on univariate analysis)
(3) advanced age (on univariate analysis)
(4) ECOG performance status >= 2 (on univariate analysis, >= 3 might be more specific)
(5) increased WBC count (in univariate analysis)
